PEGylated Drugs Market Size, Industry Analysis Report, Regional Outlook (U.S., Canada, Germany, UK, Italy, France, China, India, Japan, Australia, Argentina, Brazil, Mexico, South Africa, Saudi Arabia), Application Development Potential, Price Trends, Competitive Market Share & Forecast, 2017 – 2024
Report ID: GMI1956
PEGylated Drugs Market size may grow significantly over the projected period. Rising prevalence of chronic diseases and high demand of PEGylated drugs is expected to drive business.
PEGylated drugs can be used to treat chronic disorders like cancer. Cancer is of the leading cause of death and its prevalence is rising continuously. Binding of PEG with drugs facilitates its entry into the tumor cell and to give better therapeutic results. The demand for these drugs is high as it offers different advantages such as reduced degradation by metabolic enzymes, elimination of immunogenicity and increased residence in blood. It also enhances the solubility of drugs and reduces effects of proteolytic enzymes, thus improves the bioavailability.
PEGylation refers to change in structure of protein by linking one or more polyethylene glycol (PEG) chains. It is easily soluble in organic and aqueous solutions and is non-toxic in nature. The chain binds to the drugs covalently and make it sterically stable. The polymer thus formed is non-toxic, non-antigenic, non-immunogenic, and highly water soluble. It further increases half-life of the drug and reduces dose frequency by preventing renal excretion of drugs.
Increasing protein stability and circulating half-life, and increased R&D spending are some other impact rendering factors for industry. However, adverse drug reactions associated can impede market growth during forecast period. Attachment of PEG with drugs however, comes with certain limitations. In some cases, intravenous administration resulted in hypersensitivity reactions and blood clots. In other cases, it resulted in antibody production in body and has also shown hypersensitivity reactions when administered with laxatives.
PEGylation products consists of different reagents including linkers, cross-linkers, and labels. Different reagents include AMINE, CARBOXYL, and CARBOXYL PEGylation. Drugs currently being used in the treatment of cancer, chronic kidney diseases, hepatitis, multiple sclerosis, hemophilia, and gastrointestinal disorders. Mircera, an erythropoiesis stimulating agent is approved by FDA for treatment of anemia associated with chronic renal failure. PEG-INTRON and PEGASYS are other FDA approved products for treatment of hepatitis C.
Different proteins such as mAbs, colony stimulating factors, recombinant factor vii, interferons and many more can be coupled with PEG molecule. PEGylated interferon is a class of drugs that includes Peginterferon alfa 2a and alfa 2b. These are FDA approved and used for the treatment of hepatitis C and in some cases for hepatitis B.
The process is primarily used by pharmaceutical and biotechnology companies, research institutes and contract research organization. In chronic conditions, frequent dosing can reduce patient’s compliance to the treatment. Research institute are working relentlessly to reduce the dose using PEGylation techniques. Its therapeutic agents are expanding clinical pipelines for many biotech companies as the technique is now being applied to peptides, aptamers, and smaller molecules.
As per center for disease control and prevention, in U.S. around 400 babies suffer from hemophilia each year. Demand for long acting drugs with extended half-life to treat such diseases is increasing in the region. The increased adoption of protein based drugs is expected to drive the U.S. market over forecast period.
Asia pacific is predicted to show significant growth due to rising prevalence of chronic diseases like cancer and arthritis. For instance, in China cancer caused 2.8 million deaths and 4.3 million new cases were diagnosed. The high prevalence of such diseases will boost the regional revenue share over the forecast timeframe.
Companies operating in business include Thermo Fisher Scientific, Merck, Johnson & Johnson, Creative PEGworks, NOF, Quanta BioDesign Celares Biomatrik, and Iris Biotech Laysan Bio. To gain competitive advantage companies are adopting strategies like mergers and acquisitions, partnerships, collaborations, and geographical expansions. For instance, in June 2015, Merck entered into a collaboration with Celares, a German based firm involved in the business of PEGylation and chemical modification of biopharmaceuticals. The collaboration expanded Merck’s product of portfolio of functionalized products.
What Information does this report contain?
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security